论文部分内容阅读
目的研究在临床免疫检验中实施质量控制的作用以及措施。方法本院于2010年起在临床免疫检验工作中实施免疫检验分析质量控制,总结其有效措施,并将实施该措施前后5年时间内本院免疫检验结果的质量进行比较。结果实施质量控制前甲状腺功能检验变异指数为(56.2±4.8),血清胰岛素(INS)为(68.6±5.7),C肽(C-P)指数为(62.5±2.9),胰岛素抗体(IAb)指数为(58.3±4.8),甲胎蛋白(AFP)指数为(46.5±4.5),癌胚抗原(CEA)指数为(61.4±6.8),钙125指数为(52.6±4.2),钙199指数为(48.6±5.2),人绒毛膜促性腺激素(β-HCG)指数为(61.5±3.5),高于实施后的(31.3±3.5)、(39.5±5.1)、(38.2±3.5)、(26.5±3.3)、(24.8±3.6)、(40.5±3.5)、(30.2±3.8)、(28.5±3.9)、(38.5±2.4),差异有统计学意义(P<0.05)。结论在临床免疫检验工作中实施免疫检验分析质量控制能够有效提高检验的质量,并减少变异情况的发生,对于患者疾病的治疗有重要意义。
Objective To study the role and measures of quality control in clinical immunoassay. Methods The hospital from 2010 in the clinical immunoassay in the implementation of the quality control of immunoassay, summarize the effective measures, and the implementation of this measure within 5 years before the quality of our hospital immunity test results were compared. Results Before the implementation of quality control, the index of variation of thyroid function was (56.2 ± 4.8), the serum insulin (68.6 ± 5.7), the C peptide index (62.5 ± 2.9) and the index of insulin antibody (IAb) 58.3 ± 4.8), AFP (46.5 ± 4.5), CEA (61.4 ± 6.8), calcium 125 index (52.6 ± 4.2) and calcium 199 index (48.6 ± 5.21), (51.5 ± 5.1), (38.2 ± 3.5), (26.5 ± 3.3) and (61.5 ± 3.5) , (24.8 ± 3.6), (40.5 ± 3.5), (30.2 ± 3.8), (28.5 ± 3.9) and (38.5 ± 2.4) respectively. There was significant difference between the two groups (P <0.05). Conclusions The quality control of immunoassay in clinical immunoassay can effectively improve the quality of testing and reduce the occurrence of mutation, which is of great significance for the treatment of patients’ diseases.